Mark J Niciu

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Building 10 CRC, Room 7 5545, Bethesda, MD, 20892, USA
    J Neural Transm 121:907-24. 2014
  2. pmc Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institutes of Health National Institute of Mental Health, Bethesda, Maryland 20814 9692 email
    Annu Rev Pharmacol Toxicol 54:119-39. 2014
  3. ncbi request reprint Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder
    Mark J Niciu
    Yale University, Department of Psychiatry Connecticut Mental Health Center CMHC, Clinical Neuroscience Research Unit CNRU, New Haven, Connecticut, USA
    J Psychopharmacol 27:651-4. 2013
  4. ncbi request reprint Clinical predictors of ketamine response in treatment-resistant major depression
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program IRP, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, Maryland
    J Clin Psychiatry 75:e417-23. 2014
  5. ncbi request reprint Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety
    Elizabeth D Ballard
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA Electronic address
    J Psychiatr Res 58:161-6. 2014
  6. ncbi request reprint Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine
    Dawn F Ionescu
    Bldg 10, CRC Room 7 5545, 10 Center Drive, MSC 1282, Bethesda, MD 20892
    J Clin Psychiatry 75:e932-8. 2014
  7. pmc Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder
    Mark J Niciu
    1 National Institutes of Health National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, Bethesda, Maryland, USA
    CNS Spectr 18:242-51. 2013
  8. pmc Neurobiology of anxious depression: a review
    Dawn F Ionescu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Depress Anxiety 30:374-85. 2013
  9. pmc Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Maryland
    Depress Anxiety 31:297-307. 2014
  10. pmc Do the dissociative side effects of ketamine mediate its antidepressant effects?
    David A Luckenbaugh
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, MD USA
    J Affect Disord 159:56-61. 2014

Collaborators

Detail Information

Publications15

  1. pmc Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Building 10 CRC, Room 7 5545, Bethesda, MD, 20892, USA
    J Neural Transm 121:907-24. 2014
    ..We will finally conclude by offering potential future directions necessary to realize the enormous therapeutic promise of glutamatergic antidepressants...
  2. pmc Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institutes of Health National Institute of Mental Health, Bethesda, Maryland 20814 9692 email
    Annu Rev Pharmacol Toxicol 54:119-39. 2014
    ....
  3. ncbi request reprint Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder
    Mark J Niciu
    Yale University, Department of Psychiatry Connecticut Mental Health Center CMHC, Clinical Neuroscience Research Unit CNRU, New Haven, Connecticut, USA
    J Psychopharmacol 27:651-4. 2013
    ..We conclude that there remains insufficient data on therapeutic ketamine in the presence of comorbid psychiatric disorders to promote its off-label use in a non-research milieu. ..
  4. ncbi request reprint Clinical predictors of ketamine response in treatment-resistant major depression
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program IRP, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, Maryland
    J Clin Psychiatry 75:e417-23. 2014
    ..Clinical predictors may identify those more likely to benefit from ketamine within clinically heterogeneous populations...
  5. ncbi request reprint Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety
    Elizabeth D Ballard
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA Electronic address
    J Psychiatr Res 58:161-6. 2014
    ..The aim of this analysis was to evaluate whether ketamine has an impact on suicidal thoughts, independent of depressive and anxiety symptoms...
  6. ncbi request reprint Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine
    Dawn F Ionescu
    Bldg 10, CRC Room 7 5545, 10 Center Drive, MSC 1282, Bethesda, MD 20892
    J Clin Psychiatry 75:e932-8. 2014
    ....
  7. pmc Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder
    Mark J Niciu
    1 National Institutes of Health National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, Bethesda, Maryland, USA
    CNS Spectr 18:242-51. 2013
    ..Even in the past decade, intracellular dysfunction in numerous neuroprotective/apoptotic cascades appears important in the pathophysiology and may be a future target for pharmacological interventions of BD. ..
  8. pmc Neurobiology of anxious depression: a review
    Dawn F Ionescu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Depress Anxiety 30:374-85. 2013
    ..Because exploring the neurobiology of this depressive subtype is important for improving diagnosis, prognosis, and treatment, enrichment strategies to decrease heterogeneity within the field should be employed for future research...
  9. pmc Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Maryland
    Depress Anxiety 31:297-307. 2014
    ..In sum, the combination of target engagement and well-qualified disease-related measures are crucial to improve our pathophysiological understanding, personalize treatment selection, and expand our armamentarium of novel therapeutics...
  10. pmc Do the dissociative side effects of ketamine mediate its antidepressant effects?
    David A Luckenbaugh
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, MD USA
    J Affect Disord 159:56-61. 2014
    ..Psychotomimetic symptoms, dissociation and hemodynamic changes are known side effects of ketamine, but it is unclear if these side effects relate to its antidepressant efficacy...
  11. ncbi request reprint Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder
    Mark J Niciu
    1 National Institutes of Health NIH National Institute of Mental Health NIMH, Experimental Therapeutics and Pathophysiology Branch ETPB, Intramural Research Program, Bethesda, Maryland, USA
    CNS Spectr 18:231-41. 2013
    ..Throughout this discourse, we will highlight potential intracellular targets for therapeutic intervention. Finally, future clinical implications are discussed. ..
  12. pmc Defining anxious depression: a review of the literature
    Dawn F Ionescu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    CNS Spectr 18:252-60. 2013
    ....
  13. pmc Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?
    Mark J Niciu
    Yale University Department of Psychiatry Connecticut Mental Health Center CMHC, Clinical Neuroscience Research Unit CNRU, New Haven, CT, USA
    World J Biol Psychiatry 15:2-16. 2014
    ....
  14. ncbi request reprint Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder
    Chadi G Abdallah
    Abraham Ribicoff Research Facilities, Connecticut Mental Health Center CMHC, Department of Psychiatry, Yale University School of Medicine, New Haven, Conn, USA
    Psychother Psychosom 83:298-307. 2014
    ..In light of these findings we sought to determine if baseline GABA levels predict treatment response and to broaden the analysis to other metabolites and neurotransmitters in this larger study...
  15. pmc NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia
    Alan Anticevic
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 109:16720-5. 2012
    ..Together, the present findings establish links between glutamate's role in the organization of large-scale anticorrelated neural systems, cognition, and symptoms associated with schizophrenia in humans...